Quantcast
Home > Quotes > NKTR
NKTR

Nektar Therapeutics Common Stock (NKTR) Quote & Summary Data

$33.4
*  
1.25
3.89%
Get NKTR Alerts
*Delayed - data as of May 21, 2019 15:41 ET  -  Find a broker to begin trading NKTR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    NKTR Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 33.40 / $ 33.42
1 Year Target
69
Today's High / Low
$ 33.47 / $ 32.33
Share Volume
1,119,232
50 Day Avg. Daily Volume
1,630,968
Previous Close
$ 32.15
52 Week High / Low
$ 92.17 / $ 29.2208
Market Cap
5,821,853,633
P/E Ratio
9.49
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ 3.52
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.3

Intraday Chart

Shares Traded

Share Volume:
1,119,232
50 Day Avg. Daily Volume:
1,630,968

P/E Ratio

P/E Ratio:
9.49
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ 3.52

Trading Range

The current last sale of $33.40 is 14.30% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 33.47 $ 92.17
 Low: $ 32.33 $ 29.2208

ETFs with NKTR as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.58% WisdomTree U.S. MidCap Fund (EZM) +6.50 (20.12%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Nektar Therapeutics is a research-based biopharmaceutical company focused on discovering and developing innovative medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes potential therapies for cancer, autoimmune disease and chronic pain. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build long-term stockholder value. We refer to our drug candidates where we retain at least U.S. commercial rights as "proprietary programs" and our other drug candidate programs that we have licensed U.S.  ... More ...  



Risk Grade

Where does NKTR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 32.33
Open Date:
May 21, 2019
Close Price:
$ 32.15
Close Date:
May 20, 2019


Consensus Recommendation

Analyst Info